NovImmune masters three different, established and validated technologies in house:

• The UltiMAb system to obtain fully human therapeutic monoclonal antibodies using transgenic mice (technology licensed from Medarex),
• Antibody display selection, that is the selection of fully human antibodies displayed on bacteriophages (technology pioneered and developed by CAT)
• Humanization, that is the grafting of the small sequences responsible for the recognition and binding of the antigen from a non-human species to a fully human mAb backbone